Boston Scientific Corp. (NYSE:BSX)‘s stock had its “neutral” rating reiterated by Zacks in a note issued to investors on Monday, Stock Ratings Network reports. They currently have a $12.00 target price on the stock. Zacks‘ target price indicates a potential upside of 3.27% from the stock’s previous close.
BSX has been the subject of a number of other recent research reports. Analysts at BMO Capital Markets raised their price target on shares of Boston Scientific Corp. from $10.00 to $11.00 in a research note to investors on Friday. They now have a “market perform” rating on the stock. Separately, analysts at Barclays raised their price target on shares of Boston Scientific Corp. from $12.00 to $13.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Finally, analysts at Deutsche Bank raised their price target on shares of Boston Scientific Corp. from $11.00 to $13.00 in a research note to investors on Friday. They now have a “hold” rating on the stock. Fifteen research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $10.10.
Shares of Boston Scientific Corp. (NYSE:BSX) traded down 0.35% on Monday, hitting $11.5799. The stock had a trading volume of 4,790,203 shares. Boston Scientific Corp. has a 52-week low of $5.04 and a 52-week high of $12.16. The stock has a 50-day moving average of $11. and a 200-day moving average of $9.12. The company’s market cap is $15.504 billion.
Boston Scientific Corp. (NYSE:BSX) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.08. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.73 billion. During the same quarter in the previous year, the company posted $0.16 earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis. On average, analysts predict that Boston Scientific Corp. will post $0.45 earnings per share for the current fiscal year.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.